Al Bahar S, Pandita R, Bavishi K, Savani B
Department of Hematology, Kuwait Cancer Control Centre, Shuwaikh.
Neoplasma. 1999;46(1):61-5.
Twenty one adult patients with previously untreated acute myeloblastic leukemia (AML) were treated with sequential mitoxantrone and standard dose cytosine arabinoside remission induction therapy. The median age was 33 years (range 17-56 years). Complete remission (CR) was achieved in 80% (17/21 cases) and 76% (16/21 cases) achieved CR after one course of induction therapy. The median duration of disease free survival was 9 months with an actuarial disease free survival of 22% at 43 months. The non-hematological toxicity was acceptable. We conclude that sequential mitoxantrone and cytosine arabinoside combination therapy is an effective antileukemic regimen which produces high CR rates in previously untreated adult patients with AML.
21例既往未经治疗的成年急性髓细胞白血病（AML）患者接受了米托蒽醌序贯标准剂量阿糖胞苷缓解诱导治疗。中位年龄为33岁（范围17 - 56岁）。80%（17/21例）达到完全缓解（CR），76%（16/21例）在一个疗程诱导治疗后达到CR。无病生存的中位持续时间为9个月，43个月时精算无病生存率为22%。非血液学毒性可接受。我们得出结论，米托蒽醌序贯阿糖胞苷联合治疗是一种有效的抗白血病方案，在既往未经治疗的成年AML患者中可产生高CR率。
